Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD

Clinical Neuropharmacology

Volumn 24, Issue 4, 2001, Pages 214-220

  Suchowersky, O ^a   Bailey, P ^a   Pourcher, E ^a   Bulger, L ^a   Facciponte, G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Dosage comparison; Nonfluctuating patients; Parkinson's disease; Tolcapone

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; TOLCAPONE;

ADULT; ANOREXIA; ARTICLE; CANADA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SOMNOLENCE;

ADULT; AGED; ANTIPARKINSON AGENTS; BENZOPHENONES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE;

EID: 0034905732     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200107000-00004     Document Type: Article

References (19)

1. Clinical pharmacokinetics of anti-parkinsonian drugs
2. Treatment of Parkinson's disease
3. Parkinson's disease
4. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease
5. Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease
6. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in patients with Parkinson's disease
7. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: Preclinical and clinical findings
8. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa
9. Treatment strategies for extension of levodopa effect
10. Central mechanisms and levodopa response fluctuations in Parkinson's disease
11. Parkinson's disease
12. Tolcapone added to levodopa in stable patients with Parkinson's disease: A double-blind placebo-controlled study
13. Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
14. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans
15. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects
16. Unified Parkinson's disease rating scale
17. Projection technique for evaluating surgery in Parkinson's disease
18. Parkinsonism: Onset, progression and mortality